Kevin J. Rouse

Kevin J. Rouse

Auto-generated profile, based on publicly available information

Kevin J. Rouse

Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
WHWilliam D Hazelton
William D Hazelton
MPMatthew Prest
Matthew Prest
LCLing Chen
Ling Chen
KRKevin Rouse
Kevin Rouse
EEElena B Elkin
Elena B Elkin
LHLaura J Havrilesky
Laura J Havrilesky
Background: Uterine cancer incidence and mortality are increasing, with concomitant disparities in outcomes between racial groups. Natural history modeling can evaluate risk factors, predict future trends, and simulate approaches to reducing mortality and disparities. Methods: We designed a natural history model of uterine cancer using a multistage clonal expansion design. The model is informed by National Health and Nutrition Examination Survey, National Health Examination Survey, age, time period, birth cohort, and birth certificate data on reproductive histories and body mass index (BMI). We fit and calibrated the model to Surveillance, Epidemiology, and End Results data by race and ethnicity as well as histologic subgroup. We projected future incidence and estimated the degree of contribution of BMI, reproductive history, and competing hysterectomy to excess uterine cancer incidence. Results: The model accurately replicated Surveillance, Epidemiology, and End Results incidence for endometrioid, nonendometrioid, and sarcoma subgroups for non-Hispanic Black and non-Hispanic White patients. For endometrioid, nonendometrioid, and sarcomas, BMI-attributable risks are greater for non-Hispanic White than for non-Hispanic Black patients; reproductive history–attributable risks are greater for non-Hispanic Black patients. Between 2018 and 2050, endometrioid incidence is projected to rise by 64.9% in non-Hispanic Black individuals and17.5% in non-Hispanic White individuals; the projected rise for the nonendometrioid subgroup is 41.4% in non-Hispanic Black individuals and 22.5% in non-Hispanic White individuals; the sarcoma incidence projected increase is 36% in non-Hispanic Black individuals and 29.2% in non-Hispanic White individuals. Conclusions: Uterine cancer risk is substantially explained by reproductive history and BMI, with differences observed between non-Hispanic Black and non-Hispanic White individuals and future projections indicating perpetuation of disparities. Lower rates of hysterectomy and rising obesity rates will likely contribute to continued increases in uterine cancer incidence.

1 July 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
JWJason D. Wright
Jason D. Wright
MPMatthew T. Prest
Matthew T. Prest
JFJennifer S. Ferris
Jennifer S. Ferris
LCLing Chen
Ling Chen
XXXiao Xu
Xiao Xu
EEElena B. Elkin
Elena B. Elkin
Background: To develop a natural history model for uterine cancer calibrated to population-based incidence and mortality data to project future trends in the disease through 2050. Methods: We developed a state-transition microsimulation model of uterine cancer. The model begins at 18 years of age and simulates Black and White patients, includes transition states for precursor lesions, and separately models endometrioid and nonendometrioid tumors. The model was calibrated to population-based incidence and mortality data using parameter extrapolation. Results: The model closely fit population-based incidence and mortality data of uterine cancer. From 2020 to 2050, the incidence of uterine cancer is projected to increase in White women to 74.2 cases per 100,000 (compared with 57.7 cases per 100,000 in 2018) and increase to 86.9 per 100,000 (compared with 56.8 cases per 100,000 in 2018) in Black women. Among White women, incidence-based mortality will increase from 6.1 per 100,000 in 2018 to 11.2 per 100,000 in 2050, whereas incidence-based mortality in Black women will increase from 14.1 per 100,000 to 27.9 per 100,000. Endometrioid tumors are expected to increase considerably in both White and Black women; White women will experience only a slight increase in nonendometrioid tumors, whereas the incidence of these tumors will increase substantially in Black women. Conclusions: The incidence and mortality of uterine cancer are projected to increase substantially over the next three decades. Black women will experience a disproportionate increase in the disease. Impact: Projecting the incidence and mortality of uterine cancer can facilitate future cancer control efforts.

1 July 2025
Verified
Other
Open access
JWJason D. Wright
Jason D. Wright
MPMatthew T. Prest
Matthew T. Prest
JFJennifer S. Ferris
Jennifer S. Ferris
LCLing Chen
Ling Chen
XXXiao Xu
Xiao Xu
EEElena B. Elkin
Elena B. Elkin
Supplemental Table 7: Observed and predicted stage distribution for uterine cancer.

1 July 2025
Verified
Other
Open access
JWJason D. Wright
Jason D. Wright
MPMatthew T. Prest
Matthew T. Prest
JFJennifer S. Ferris
Jennifer S. Ferris
LCLing Chen
Ling Chen
XXXiao Xu
Xiao Xu
EEElena B. Elkin
Elena B. Elkin
Supplemental Table 4: Transition bounds within the model.

1 July 2025
Verified
Other
Open access
JWJason D. Wright
Jason D. Wright
MPMatthew T. Prest
Matthew T. Prest
JFJennifer S. Ferris
Jennifer S. Ferris
LCLing Chen
Ling Chen
XXXiao Xu
Xiao Xu
EEElena B. Elkin
Elena B. Elkin
Supplemental Table 3: Variables available to define extent of disease and AJCC stage.

1 July 2025
Verified
Other
Open access
JWJason D. Wright
Jason D. Wright
MPMatthew T. Prest
Matthew T. Prest
JFJennifer S. Ferris
Jennifer S. Ferris
LCLing Chen
Ling Chen
XXXiao Xu
Xiao Xu
EEElena B. Elkin
Elena B. Elkin
Supplemental Table 2: Histologic groupings from SEER 18.